EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson’s Disease Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Mice

Łukasz A Poniatowski, Ilona Joniec-Maciejak, Adriana Wawer, Anna Sznejder-Pachołek, Ewa Machaj, Katarzyna Ziętal, Dagmara Mirowska-Guzel

Molecular Neurobiology · 2024

DOI: 10.1007/s12035-024-04161-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Neurobiology, 2024. Verfasst von Łukasz A Poniatowski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B…. Hauptthemen laut MEDLINE: Mice, Inbred C57BL, Disease Models, Animal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease is one of the most common neurodegenerative disorders characterized by a multitude of motor and non-motor clinical symptoms resulting from the progressive and long-lasting abnormal loss of nigrostriatal dopaminergic neurons. Currently, the available treatments for patients with Parkinson’s disease are limited and exert only symptomatic effects, without adequate signs of delaying or stopping the progression of the disease. Atsttrin constitutes the bioengineered protein which ultrastructure is based on the polypeptide chain frame of the progranulin (PGRN), which exerts anti-inflammatory effects through the inhibition of TNFα. The conducted preclinical studies suggest that the therapeutic implementation of Atsttrin may be potentially effective in the treatment of neurodegenerative diseases that are associated with the occurrence of neuroinflammatory processes. The aim of the proposed study was to investigate the effect of direct bilateral intracerebral administration of Atsttrin using stereotactic methods in the preclinical C57BL/6 mouse model of Parkinson’s disease inducted by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. The analysis of the dose dependency effects of the increasing doses of Atsttrin has covered a number of parameters and markers regarding neurodegenerative processes and inflammatory responses including IL-1α, TNFα, IL-6, TH, and TG2 mRNA expressions. Accordingly, the evaluation of the changes in the neurochemical profile included DA, DOPAC, 3-MT, HVA, NA, MHPG, 5-HT, and 5-HIAA concentration levels. The intracerebral administration of Atsttrin into the striatum effectively attenuated the neuroinflammatory reaction in evaluated neuroanatomical structures. Furthermore, the partial restoration of monoamine content and its metabolic turnover were observed. In this case, taking into account the previously described pharmacokinetic profile and extrapolated bioavailability as well as the stability characteristics of Atsttrin, an attempt was made to describe as precisely as possible the quantitative and qualitative effects of increasing doses of the compound within the brain tissue microenvironment in the presented preclinical model of the disease. Collectively, this findings demonstrated that the intracerebral administration of Atsttrin may represent a potential novel therapeutic method for the treatment of Parkinson’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mice, Inbred C57BLDisease Models, AnimalAnimalsMaleDose-Response Relationship, Drug1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineMiceParkinson DiseaseTyrosine 3-Monooxygenase

Stichwörter der Autor:innen

AtsttrinInflammatory reactionMPTPNeurodegenerationParkinson’s diseaseProgranulin

Substanzen

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineTyrosine 3-Monooxygenase

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B, 02-097, Warsaw, Poland.
  • Department of Neurosurgery, Dietrich-Bonhoeffer-Klinikum, Salvador-Allende-Straße 30, 17036, Neubrandenburg, Germany.
  • Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B, 02-097, Warsaw, Poland. ijoniec@wum.edu.pl.

Zitieren

APA

Poniatowski, Ł. A., Joniec-Maciejak, I., Wawer, A., Sznejder-Pachołek, A., Machaj, E., Ziętal, K., & Mirowska-Guzel, D. (2024). Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson’s Disease Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Mice. Molecular Neurobiology. https://doi.org/10.1007/s12035-024-04161-0

Vancouver

Poniatowski ŁA, Joniec-Maciejak I, Wawer A, Sznejder-Pachołek A, Machaj E, Ziętal K, et al. Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson’s Disease Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Mice. Molecular Neurobiology. 2024. doi:10.1007/s12035-024-04161-0

BibTeX
@article{Poniatowski2024,
  author = {Poniatowski, Łukasz A and Joniec-Maciejak, Ilona and Wawer, Adriana and Sznejder-Pachołek, Anna and Machaj, Ewa and Ziętal, Katarzyna and Mirowska-Guzel, Dagmara},
  title = {Dose-Ranging Effects of the Intracerebral Administration of Atsttrin in Experimental Model of Parkinson’s Disease Induced by 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Mice},
  journal = {Molecular Neurobiology},
  year = {2024},
  doi = {10.1007/s12035-024-04161-0}
}
Kostenlos starten →